{"product_id":"lly-ansoff-matrix","title":"Eli Lilly and Company (LLY): Ansoff Matrix [June-2026 Updated]","description":"\u003cp\u003eThis ready-made analysis gives you a practical growth strategy view of Company Name, showing how it can expand U.S. formulary access, scale self-pay sales through Company Name Direct, ease supply limits with more manufacturing capacity, defend share against compounded-copy products, and grow approved obesity, diabetes, and migraine brands. It also maps market expansion through additional ex-U.S. launches, product development through needle-free obesity options, next-generation obesity and Alzheimer's therapies, and diversification into sleep medicine, vaccines, neurology, oncology, and genetic medicine, while highlighting the key commercial and regulatory risks behind each move.\u003c\/p\u003e\u003ch2\u003eEli Lilly and Company - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eEli Lilly and Company's market penetration strategy in the U.S. is built on 4 numbers that matter: \u003cstrong\u003e$1,086.37\u003c\/strong\u003e for the branded pen list price, \u003cstrong\u003e$399\u003c\/strong\u003e to \u003cstrong\u003e$599\u003c\/strong\u003e for LillyDirect vial pricing, \u003cstrong\u003e$11.54 billion\u003c\/strong\u003e in Mounjaro sales, and \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e in Zepbound sales.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eExpand Zepbound and Mounjaro formulary access in the U.S.\u003c\/h2\u003e\n\u003cp\u003eZepbound and Mounjaro cover \u003cstrong\u003e6\u003c\/strong\u003e dose strengths each: \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, and \u003cstrong\u003e15 mg\u003c\/strong\u003e. That dose ladder supports payer access because patients can stay inside the branded channel as their dose changes.\u003c\/p\u003e\n\u003cp\u003eThe U.S. list price for Zepbound pens is \u003cstrong\u003e$1,086.37\u003c\/strong\u003e per \u003cstrong\u003e4-week\u003c\/strong\u003e supply. LillyDirect's vial prices are \u003cstrong\u003e$399\u003c\/strong\u003e for \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e for \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e$499\u003c\/strong\u003e for \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, and \u003cstrong\u003e$599\u003c\/strong\u003e for \u003cstrong\u003e10 mg\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct or channel\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eMarket penetration role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound pen list price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,086.37\u003c\/strong\u003e per 4-week supply\u003c\/td\u003e\n\u003ctd\u003eReference price for insured and self-pay access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound vial 2.5 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$399\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStarter-dose self-pay conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound vial 5 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$549\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMaintenance self-pay conversion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound vial 7.5 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$499\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigher-dose cash access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound vial 10 mg\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$599\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigher-dose cash access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro 2024 sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.54 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDiabetes franchise scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound 2024 sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObesity franchise scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly and Company 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunding for access and supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eScale LillyDirect to convert more self-pay patients.\u003c\/h2\u003e\n\u003cp\u003eLillyDirect makes the cash channel explicit at \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$499\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e, and \u003cstrong\u003e$599\u003c\/strong\u003e instead of leaving patients at a single branded pen price of \u003cstrong\u003e$1,086.37\u003c\/strong\u003e. The monthly run rate is \u003cstrong\u003e$4,788\u003c\/strong\u003e at \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$5,988\u003c\/strong\u003e at \u003cstrong\u003e$499\u003c\/strong\u003e, \u003cstrong\u003e$6,588\u003c\/strong\u003e at \u003cstrong\u003e$549\u003c\/strong\u003e, and \u003cstrong\u003e$7,188\u003c\/strong\u003e at \u003cstrong\u003e$599\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e x \u003cstrong\u003e12\u003c\/strong\u003e = \u003cstrong\u003e$4,788\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$499\u003c\/strong\u003e x \u003cstrong\u003e12\u003c\/strong\u003e = \u003cstrong\u003e$5,988\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$549\u003c\/strong\u003e x \u003cstrong\u003e12\u003c\/strong\u003e = \u003cstrong\u003e$6,588\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$599\u003c\/strong\u003e x \u003cstrong\u003e12\u003c\/strong\u003e = \u003cstrong\u003e$7,188\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat creates \u003cstrong\u003e4\u003c\/strong\u003e direct-to-patient price points, which is more flexible than a single pen price and gives Eli Lilly and Company a clearer self-pay path for obesity treatment.\u003c\/p\u003e\n\n\u003ch2\u003eUse new manufacturing capacity to remove supply constraints.\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company has announced more than \u003cstrong\u003e$27 billion\u003c\/strong\u003e of U.S. manufacturing expansion. That amount matters because market penetration is limited when demand exists but dose supply does not.\u003c\/p\u003e\n\u003cp\u003eZepbound and Mounjaro each run across \u003cstrong\u003e6\u003c\/strong\u003e labeled dose strengths, so output has to support multiple doses at the same time: \u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, and \u003cstrong\u003e15 mg\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand\u003c\/td\u003e\n\u003ctd\u003eDose strengths\u003c\/td\u003e\n\u003ctd\u003eUse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.5 mg\u003c\/strong\u003e, \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e7.5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e12.5 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eObesity and chronic weight management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmgality\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e240 mg\u003c\/strong\u003e loading dose, \u003cstrong\u003e120 mg\u003c\/strong\u003e monthly\u003c\/td\u003e\n\u003ctd\u003eMigraine prevention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eDefend tirzepatide share against compounded-copy products.\u003c\/h2\u003e\n\u003cp\u003eThe defense starts with price separation. A patient facing a pen list price of \u003cstrong\u003e$1,086.37\u003c\/strong\u003e can move to a branded vial at \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$499\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e, or \u003cstrong\u003e$599\u003c\/strong\u003e instead of comparing only against a compounded alternative.\u003c\/p\u003e\n\u003cp\u003eThe gap to the list price is \u003cstrong\u003e$687.37\u003c\/strong\u003e at \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$587.37\u003c\/strong\u003e at \u003cstrong\u003e$499\u003c\/strong\u003e, \u003cstrong\u003e$537.37\u003c\/strong\u003e at \u003cstrong\u003e$549\u003c\/strong\u003e, and \u003cstrong\u003e$487.37\u003c\/strong\u003e at \u003cstrong\u003e$599\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThat gap gives Eli Lilly and Company a branded cash option in the same dosage range, from \u003cstrong\u003e2.5 mg\u003c\/strong\u003e through \u003cstrong\u003e10 mg\u003c\/strong\u003e in the direct channel.\u003c\/p\u003e\n\n\u003ch2\u003eGrow use of approved obesity, diabetes, and migraine brands.\u003c\/h2\u003e\n\u003cp\u003eThe obesity and diabetes franchise is concentrated in tirzepatide, with Mounjaro at \u003cstrong\u003e$11.54 billion\u003c\/strong\u003e in 2024 sales and Zepbound at \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e in 2024 sales. Combined, that is \u003cstrong\u003e$16.44 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eEmgality gives Eli Lilly and Company a migraine product with a \u003cstrong\u003e240 mg\u003c\/strong\u003e start and \u003cstrong\u003e120 mg\u003c\/strong\u003e monthly maintenance dosing. That dosing pattern supports repeated use in an approved migraine category, separate from the \u003cstrong\u003e2.5 mg\u003c\/strong\u003e to \u003cstrong\u003e15 mg\u003c\/strong\u003e tirzepatide franchise.\u003c\/p\u003e\n\u003cp\u003eEli Lilly and Company's 2024 revenue of \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e shows how much of the top line is already coming from existing U.S. brands rather than new launches.\u003c\/p\u003e\u003ch2\u003eEli Lilly and Company - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\u003cp\u003eMarket development at Eli Lilly and Company is tied to the move from \u003cstrong\u003e$34.1 billion\u003c\/strong\u003e in 2023 revenue to \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2024 revenue, a gain of \u003cstrong\u003e$10.9 billion\u003c\/strong\u003e or \u003cstrong\u003e31.9%\u003c\/strong\u003e. The current ex-U.S. growth base is strongest in tirzepatide and donanemab, because both already have real approval and sales history.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eReal-life market development fact\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro\u003c\/td\u003e\n\u003ctd\u003eFDA approval for type 2 diabetes; European Commission authorization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMay 2022\u003c\/strong\u003e; \u003cstrong\u003eSeptember 2022\u003c\/strong\u003e; \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e in 2024 revenue\u003c\/td\u003e\n\u003ctd\u003eShows an existing product that can be rolled into more ex-U.S. markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003eFDA approval for chronic weight management\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNovember 2023\u003c\/strong\u003e; \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e in 2024 revenue\u003c\/td\u003e\n\u003ctd\u003eSupports obesity access expansion where coverage is emerging\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisunla\u003c\/td\u003e\n\u003ctd\u003eFDA approval for early symptomatic Alzheimer's disease\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eJuly 2024\u003c\/strong\u003e; \u003cstrong\u003e1,736\u003c\/strong\u003e participants in TRAILBLAZER-ALZ 2\u003c\/td\u003e\n\u003ctd\u003eGives Lilly a large evidence base for wider international filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly and Company\u003c\/td\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$34.1 billion\u003c\/strong\u003e in 2023; \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2024\u003c\/td\u003e\n\u003ctd\u003eFunds regulatory, supply, reimbursement, and partner costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMounjaro\u003c\/strong\u003e is the clearest ex-U.S. rollout asset because the same tirzepatide molecule has already produced \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e in 2024 revenue. The approval path moved from \u003cstrong\u003eMay 2022\u003c\/strong\u003e in the U.S. to \u003cstrong\u003eSeptember 2022\u003c\/strong\u003e in Europe, which shows that Lilly can take one product through multiple regulatory systems without rebuilding the molecule.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e of 2024 revenue gives Lilly a large base for registration and launch costs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMay 2022\u003c\/strong\u003e and \u003cstrong\u003eSeptember 2022\u003c\/strong\u003e approvals show that the product already has cross-border regulatory precedent.\u003c\/li\u003e\n\u003cli\u003eThe same molecule can support diabetes and obesity commercial plans across different payer systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eZepbound\u003c\/strong\u003e strengthens market development where obesity coverage is still opening. The FDA approval came in \u003cstrong\u003eNovember 2023\u003c\/strong\u003e, and 2024 revenue reached \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e. Together, \u003cstrong\u003eMounjaro\u003c\/strong\u003e and \u003cstrong\u003eZepbound\u003c\/strong\u003e generated \u003cstrong\u003e$16.4 billion\u003c\/strong\u003e in 2024, equal to \u003cstrong\u003e36.4%\u003c\/strong\u003e of Eli Lilly and Company's \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e total revenue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKisunla\u003c\/strong\u003e creates a different international path because Alzheimer's disease expansion depends on regulatory review, specialty diagnostics, and physician access. The FDA approval came in \u003cstrong\u003eJuly 2024\u003c\/strong\u003e, and TRAILBLAZER-ALZ 2 enrolled \u003cstrong\u003e1,736\u003c\/strong\u003e participants. That trial size matters because wider approvals usually require large, controlled data sets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eCalculation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e - \u003cstrong\u003e$34.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10.9 billion\u003c\/strong\u003e ÷ \u003cstrong\u003e$34.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro plus Zepbound\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e + \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined share of 2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e36.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$16.4 billion\u003c\/strong\u003e ÷ \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2024 revenue supports ex-U.S. launch spending.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$16.4 billion\u003c\/strong\u003e from Mounjaro and Zepbound shows the scale of the tirzepatide platform.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,736\u003c\/strong\u003e participants in Kisunla's pivotal study support broader filing packages.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e31.9%\u003c\/strong\u003e annual revenue growth shows that geographic expansion is already moving the top line.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLocal partnerships matter because country entry requires registration, reimbursement, supply, and physician education in each market. With a \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e revenue base, Lilly can fund local commercial teams and partner-led launches without relying on one market alone.\u003c\/p\u003e\n\u003ch2\u003eEli Lilly and Company - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company's product development pipeline is built around \u003cstrong\u003e14.7%\u003c\/strong\u003e, \u003cstrong\u003e20.9%\u003c\/strong\u003e, and \u003cstrong\u003e24.2%\u003c\/strong\u003e obesity efficacy readouts, plus \u003cstrong\u003e1,736\u003c\/strong\u003e patients and \u003cstrong\u003e76\u003c\/strong\u003e weeks in Kisunla's pivotal Alzheimer's trial.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eRoute\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eProduct-development role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeedle-free obesity option\u003c\/td\u003e\n\u003ctd\u003eOrforglipron\u003c\/td\u003e\n\u003ctd\u003eOral, once daily\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36\u003c\/strong\u003e weeks; \u003cstrong\u003e14.7%\u003c\/strong\u003e mean weight loss\u003c\/td\u003e\n\u003ctd\u003eOral obesity product development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNext-generation obesity treatment\u003c\/td\u003e\n\u003ctd\u003eRetatrutide\u003c\/td\u003e\n\u003ctd\u003eInjectable\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48\u003c\/strong\u003e weeks; \u003cstrong\u003e24.2%\u003c\/strong\u003e mean weight loss\u003c\/td\u003e\n\u003ctd\u003eHigher-efficacy follow-on obesity therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlzheimer's disease\u003c\/td\u003e\n\u003ctd\u003eKisunla\u003c\/td\u003e\n\u003ctd\u003eIntravenous\u003c\/td\u003e\n\u003ctd\u003eFDA approval on \u003cstrong\u003eJuly 2, 2024\u003c\/strong\u003e; \u003cstrong\u003e1,736\u003c\/strong\u003e participants; \u003cstrong\u003e76\u003c\/strong\u003e weeks; \u003cstrong\u003e700 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks for the first \u003cstrong\u003e3\u003c\/strong\u003e doses, then \u003cstrong\u003e1,400 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003eBroader evidence and label development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-acting metabolic formulation\u003c\/td\u003e\n\u003ctd\u003eTirzepatide\u003c\/td\u003e\n\u003ctd\u003eOnce-weekly injectable\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e72\u003c\/strong\u003e weeks; \u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss at \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLong-acting cardiometabolic platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eNeedle-free obesity option\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrforglipron is the clearest oral obesity development track. In a \u003cstrong\u003e36\u003c\/strong\u003e-week phase 2 study, the highest dose produced \u003cstrong\u003e14.7%\u003c\/strong\u003e mean weight loss.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e36\u003c\/strong\u003e weeks\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e14.7%\u003c\/strong\u003e mean weight loss\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOnce-daily\u003c\/strong\u003e oral dosing\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdvance retatrutide\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRetatrutide posted up to \u003cstrong\u003e24.2%\u003c\/strong\u003e mean weight loss at \u003cstrong\u003e48\u003c\/strong\u003e weeks in phase 2 obesity data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e24.2%\u003c\/strong\u003e mean weight loss\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e48\u003c\/strong\u003e weeks\u003c\/li\u003e\n\u003cli\u003eTriple-agonist obesity program\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand Kisunla\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eKisunla gained FDA approval on \u003cstrong\u003eJuly 2, 2024\u003c\/strong\u003e for adults with early symptomatic Alzheimer's disease and confirmed amyloid pathology. The pivotal TRAILBLAZER-ALZ 2 study enrolled \u003cstrong\u003e1,736\u003c\/strong\u003e participants over \u003cstrong\u003e76\u003c\/strong\u003e weeks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,736\u003c\/strong\u003e participants\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e76\u003c\/strong\u003e weeks\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e700 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks for the first \u003cstrong\u003e3\u003c\/strong\u003e doses\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,400 mg\u003c\/strong\u003e every \u003cstrong\u003e4\u003c\/strong\u003e weeks after dose \u003cstrong\u003e3\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDevelop new oral and long-acting metabolic formulations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatide's SURMOUNT-1 result of \u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss at \u003cstrong\u003e72\u003c\/strong\u003e weeks at the \u003cstrong\u003e15 mg\u003c\/strong\u003e dose gives Eli Lilly and Company a real benchmark for long-acting metabolic therapy. Orforglipron's \u003cstrong\u003e14.7%\u003c\/strong\u003e oral result gives a second format with no injection step.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e72\u003c\/strong\u003e weeks\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e15 mg\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e14.7%\u003c\/strong\u003e mean weight loss\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBuild follow-on therapies from current cardiometabolic science\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEli Lilly and Company reported \u003cstrong\u003e$34.1 billion\u003c\/strong\u003e in revenue in \u003cstrong\u003e2023\u003c\/strong\u003e. That scale supports parallel development across obesity, diabetes, and Alzheimer's disease.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$34.1 billion\u003c\/strong\u003e revenue in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e24.2%\u003c\/strong\u003e retatrutide obesity readout\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e20.9%\u003c\/strong\u003e tirzepatide obesity readout\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e14.7%\u003c\/strong\u003e oral obesity readout\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eEli Lilly and Company - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$18.447 billion\u003c\/strong\u003e across \u003cstrong\u003e7\u003c\/strong\u003e disclosed acquisition deals shows the scale of Lilly's diversification into new therapeutic adjacencies.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003ctd\u003eArea\u003c\/td\u003e\n\u003ctd\u003eDisclosed value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003eLoxo Oncology\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003ctd\u003ePrevail Therapeutics\u003c\/td\u003e\n\u003ctd\u003eNeurodegeneration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.04 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003eAkouos\u003c\/td\u003e\n\u003ctd\u003eGenetic medicine\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$487 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eVersanis Bio\u003c\/td\u003e\n\u003ctd\u003eObesity and metabolic disease\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.92 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eDice Therapeutics\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003ePoint Biopharma\u003c\/td\u003e\n\u003ctd\u003eRadiopharmaceuticals\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eMorphic Holding\u003c\/td\u003e\n\u003ctd\u003eInflammation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eORX750\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.4 billion\u003c\/strong\u003e in oncology from \u003cstrong\u003e2\u003c\/strong\u003e deals\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.527 billion\u003c\/strong\u003e in neuro\/gene medicine from \u003cstrong\u003e2\u003c\/strong\u003e deals\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.6 billion\u003c\/strong\u003e in inflammation and immunology from \u003cstrong\u003e2\u003c\/strong\u003e deals\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.92 billion\u003c\/strong\u003e in obesity and metabolic disease from \u003cstrong\u003e1\u003c\/strong\u003e deal\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic area\u003c\/td\u003e\n\u003ctd\u003eDeal count\u003c\/td\u003e\n\u003ctd\u003eAggregate disclosed value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuro\/gene medicine\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.527 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflammation and immunology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObesity and metabolic disease\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.92 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e$2.635 billion\u003c\/strong\u003e average disclosed deal value\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$8.0 billion\u003c\/strong\u003e largest disclosed deal value\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$487 million\u003c\/strong\u003e smallest disclosed deal value\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45497908297877,"sku":"lly-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/lly-ansoff-matrix.png?v=1740169481","url":"https:\/\/dcf-analysis.com\/products\/lly-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}